Published in Am J Med on December 08, 2003
Essential role of insulin and insulin-like growth factor 1 receptor signaling in cardiac development and function. Mol Cell Biol (2006) 1.34
Protective effects of a compound herbal extract (Tong Xin Luo) on free fatty acid induced endothelial injury: implications of antioxidant system. BMC Complement Altern Med (2008) 0.80
Glyceraldehyde 3-phosphate dehydrogenase is a cellular target of the insulin mimic demethylasterriquinone B1. J Med Chem (2007) 0.80
Sex-related differences in the effects of the mediterranean diet on glucose and insulin homeostasis. J Nutr Metab (2014) 0.78
The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med (2005) 6.63
Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care (2005) 5.77
Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med (2011) 4.28
Costs associated with the primary prevention of type 2 diabetes mellitus in the diabetes prevention program. Diabetes Care (2003) 4.22
Detection of silent myocardial ischemia in asymptomatic diabetic subjects: the DIAD study. Diabetes Care (2004) 4.17
Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999-2002: the National Health and Nutrition Examination Survey. Diabetes Care (2006) 3.72
The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia. Diabetes Care (2014) 3.31
Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial. JAMA (2008) 3.16
Coronary heart disease risk equivalence in diabetes depends on concomitant risk factors. Diabetes Care (2006) 2.90
Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine. Diabetes Care (2011) 2.60
Cost-effectiveness of screening for pre-diabetes among overweight and obese U.S. adults. Diabetes Care (2007) 2.20
Accuracy of the SEVEN continuous glucose monitoring system: comparison with frequently sampled venous glucose measurements. J Diabetes Sci Technol (2009) 1.93
Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. J Am Coll Cardiol (2008) 1.91
Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol (2003) 1.85
An evaluation of cost sharing to finance a diet and physical activity intervention to prevent diabetes. Diabetes Care (2006) 1.51
Resolution of asymptomatic myocardial ischemia in patients with type 2 diabetes in the Detection of Ischemia in Asymptomatic Diabetics (DIAD) study. Diabetes Care (2007) 1.46
Skin intrinsic fluorescence correlates with autonomic and distal symmetrical polyneuropathy in individuals with type 1 diabetes. Diabetes Care (2011) 1.26
Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors. Arterioscler Thromb Vasc Biol (2012) 1.22
Effectiveness and cost-effectiveness of diabetes prevention among adherent participants. Am J Manag Care (2013) 1.18
Impact of computer-generated personalized goals on HbA(1c). Diabetes Care (2002) 1.14
Scientific statement: Socioecological determinants of prediabetes and type 2 diabetes. Diabetes Care (2013) 1.09
Examination of lower targets for low-density lipoprotein cholesterol and blood pressure in diabetes--the Stop Atherosclerosis in Native Diabetics Study (SANDS). Am Heart J (2006) 1.08
PREVENTION OF ATHEROSCLEROSIS WITH LDL-C LOWERING - LIPOPROTEIN CHANGES AND INTERACTIONS: THE SANDS STUDY. J Clin Lipidol (2009) 1.02
Prediction of diabetes based on baseline metabolic characteristics in individuals at high risk. Diabetes Care (2013) 1.01
Brachial artery reactivity in asymptomatic patients with type 2 diabetes mellitus and microalbuminuria (from the Detection of Ischemia in Asymptomatic Diabetics-brachial artery reactivity study). Am J Cardiol (2004) 1.01
Prevention of diabetes with pioglitazone in ACT NOW: physiologic correlates. Diabetes (2013) 0.97
Skin intrinsic fluorescence is associated with coronary artery disease in individuals with long duration of type 1 diabetes. Diabetes Care (2012) 0.96
Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study. Clin Ther (2008) 0.93
A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidone. J Clin Psychiatry (2009) 0.93
Effects of therapy in type 1 and type 2 diabetes mellitus with a peptide derived from islet neogenesis associated protein (INGAP). Diabetes Metab Res Rev (2009) 0.93
The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: the "gift" that keeps on giving! Diabetes Care (2014) 0.86
Novel pharmacologic agents for type 2 diabetes. Endocrinol Metab Clin North Am (2005) 0.83
The American Diabetes Association diabetes research perspective. Diabetes (2012) 0.82
Evaluation of in-stent restenosis in the APPROACH trial (Assessment on the Prevention of Progression by Rosiglitazone On Atherosclerosis in diabetes patients with Cardiovascular History). Int J Cardiovasc Imaging (2011) 0.82
The American Diabetes Association diabetes research perspective. Diabetes Care (2012) 0.81
Cross-sectional evaluation of noninvasively detected skin intrinsic fluorescence and mean hemoglobin a1c in type 1 diabetes. Diabetes Technol Ther (2013) 0.80
Relationship of glycemia control to lipid and blood pressure lowering and atherosclerosis: the SANDS experience. J Diabetes Complications (2011) 0.80
Should the metabolic syndrome patient with prediabetes be offered pharmacotherapy? Curr Diab Rep (2011) 0.79
A novel insulin resistance index to monitor changes in insulin sensitivity and glucose tolerance: the ACT NOW study. J Clin Endocrinol Metab (2015) 0.79
Differential effects of oral hypoglycemic agents on glucose control and cardiovascular risk. Am J Cardiol (2006) 0.78
Pramlintide: A new tool in diabetes management. Curr Diab Rep (2006) 0.78
Cost-effectiveness of lower targets for blood pressure and low-density lipoprotein cholesterol in diabetes: the Stop Atherosclerosis in Native Diabetics Study (SANDS) . J Clin Lipidol (2010) 0.77
Managing people at high risk for diabetes. Ann Intern Med (2006) 0.77
Value of peripheral vascular endothelial function in the detection of relative myocardial ischemia in asymptomatic type 2 diabetic patients who underwent myocardial perfusion imaging. J Nucl Cardiol (2006) 0.77
New concepts in diabetes: how multihormonal regulation can improve glycemic control. J Manag Care Pharm (2004) 0.76
Impact of computer-generated personalized goals on cholesterol lowering. Value Health (2005) 0.75
Combination pharmacotherapy with incretins: what works best and when? Curr Diab Rep (2008) 0.75